MARKET STRATEGY - Case study I

Client Need

SPIREN HealthCare’s client, a mid-sized Pharmaceutical firm, listed, present in China for 10+ years, wanted to develop a new strategy for its oncology portfolio, in China. The company commissioned SPIREN HealthCare to develop the strategic plan for the Oncology franchise, in China.

SPIREN HealthCare’s Contribution.

Leveraging our extensive pharmaceutical and oncology expertise, in addition to our business experience and track records in China, we have led a joint team to ensure buy-in on the approach by key stakeholders of a pragmatic market strategy. First and foremost, we have involved our client’s stakeholders in kickoff meetings, presented the process and aligned expectations. We have then developed strategic options. We have finally recommended a market strategy and presented it to the Client’s Board of Directors.

Key outcomes for the client.

SPIREN HealthCare’s oncology market strategy was fully endorsed by the Board of Directors. The client has been implementing the Execution Road Map and has commissioned SPIREN HealthCare to drive the execution of one major pillar of the market strategy. Our client is building up assets in China for its oncology franchise.

MARKET STRATEGY - Case study II

Client Need

SPIREN HealthCare’s client, a small-sized Medical Device firm, listed, present in China for 3 years, wanted to understand the attractiveness of a new indication, and associated market access barriers. The company commissioned SPIREN HealthCare to understand attractiveness and develop the market strategy for this new indication, in China.

SPIREN HealthCare’s Contribution.

Leveraging our extensive medical device expertise, in addition to our business experience and track records in China, we have first selected 25 Key Opinion Leaders from top leading hospitals in Beijing and Shanghai. We have then conducted in-depth interviews, and quantitative research. We have then developed strategic options, fully explored market access barriers, and recommended a market strategy.

Key outcomes for the client.

SPIREN HealthCare’s market strategy was fully endorsed by the Management Team. The client has been implementing the Execution Road Map.

MARKET ENTRY - Case study I

Client Need

SPIREN HealthCare’s client, a mid-sized Pharmaceutical firm, listed, present in China for 10+ years, wanted to implement a new market strategy for its oncology portfolio, in China. The company commissioned SPIREN HealthCare to drive the execution of one major pillar of the market strategy: select a Strategic Commercial Partner, which would commercialize its oncology franchise.

SPIREN HealthCare’s Contribution.

Leveraging our extensive pharmaceutical and oncology expertise, in addition to our business experience with track records in China, we have led a joint team to ensure buy-in on the approach by key stakeholders. First and foremost, we have come up with a “long list”, then a “short list”. We have then engaged lead candidates and performed Due Diligence. We have led the negotiation with the lead company (a major Chinese company, listed) and supported the development and implementation of a Partnership Agreement.

Key outcomes for the client.

SPIREN HealthCare’s recommendation was fully endorsed by the Management Team and the Board of Directors. Both Parties have signed the Partnership Agreement. This is among the critical assets for the Client. Its oncology franchise is now repositioned in our client’s most strategic country.

DUE DILIGENCE - Case Study I

Client Need

SPIREN HealthCare’s client, a top leading Private Equity firm, wanted to perform due diligence on a Medical Device company. The Private Equity firm commissioned SPIREN HealthCare to perform due diligence of this company particularly in China: current market position, potential of new products.

SPIREN HealthCare’s Contribution.

Leveraging our extensive medical device expertise, in addition to our business experience with track records in China, we have conducted in-depth interviews with Key Opinion Leaders, practitioners, Industry experts as well as primary research. We have also interviewed business partners, operations and former employees of the target company. We have then finalized our Due Diligence report.

Key outcomes for the client.

The Private Equity firm has decided not to proceed globally with the deal.